Morphine toxicity in renal failure

Ferraz Gonçalves, MD





Full Text:



Mercadante S: “The role of morphine glucuronides in cancer pain.” Palliat Med. 1999; 13: 95-104.

Lötsch J: Opioid metabolites. J Pain Symptom Manage. 2005; 29: S10-S24.

Portenoy RK, Foley KM, Stulman J, et al.: Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: Plasma profiles, steady-state concentrations and the consequences of renal failure. Pain. 1991; 47: 13-19.

Osborne RJ, Joel SP, Slevin M: Morphine intoxication in renal failure: The role of morphine-6-glucuronide. BMJ. 1986; 292: 1548-1549.

Lötsch J,. Zimmermann M, Darimont J, et al.: Does the A118G polymorphism at the m-opioid receptor gene protect against morphine-6-glucuronide toxicity? Anesthesiology. 2002; 97: 814-819.

Fainsinger R, Schoeller T, Bruera E: Methadone in the treatment of cancer pain: A review. Pain. 1993; 52: 137-147.

Lee MA, Leng MEF, Tiernan EJJ: Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med. 2001; 15: 26-34.

Murray A, Hagen NA: Hydromorphone. J Pain Symptom Manage. 2005; 29: S57-S66.

Johnson RE, Fudala PJ, Payne R: Buprenorphine: Considerations for pain management. J Pain Symptom Manage. 2005; 29: 297-326.

Dean M: Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004; 28: 497-504.

Mercadante S, Caligara M, Sapio M, et al.: Subcutaneous fentanyl infusion in a patient with bowel obstruction and renal failure. J Pain Symptom Manage. 1997; 13: 241-244.

Radbruch L, Sabatowski R, Petzke F, et al.: Transdermal fentanyl for the management of cancer pain: A survey of 1005 patients. Palliat Med. 2001; 15: 309-321.

Martin WR: Naloxone. Ann Intern Med. 1976; 85: 765-768.



  • There are currently no refbacks.